期刊文献+

血清糖类抗原125联合人附睾蛋白4检测在上皮性卵巢癌病情评估、预后生存预测中的应用研究 被引量:7

Application of the analysis of serum CA125 and HE4 in the assessment of epithelial ovarian cancer and in the prediction of the survival in patients
下载PDF
导出
摘要 目的分析血清糖类抗原125(CA125)联合人附睾蛋白4(HE4)检测在上皮性卵巢癌病情评估、预后生存预测中的应用。方法2016年5月至2017年5月54例上皮性卵巢癌患者设为观察组,选取同期进行体检的女性健康人员60例设为对照组。比较两组血清CA125、HE4表达情况,分析CA125、HE4水平与上皮性卵巢癌患者临床病理特征的关系,绘制ROC曲线,采用Keplan-meier生存对比预后情况,Logistic回归模型分析影响预后的相关因素。结果CA125及HE4在观察组中的阳性表达率均显著高于对照组(P<0.05);不同年龄、肿瘤浸润深度、病理学分级比较CA125、HE4阳性表达率差异有统计学意义(P<0.05);在FIGO分期中,Ⅲ~Ⅳ期阳性表达率明显高于Ⅰ~Ⅱ期阳性表达率(P<0.05);盆腔淋巴结阳性、腹主动脉旁淋巴结阳性、腹水的上皮性卵巢癌阳性表达率显著高于无淋巴结转移、无腹水者(P<0.05);Keplan-meier分析显示CA125及HE4表达阴性者生存期显著长于表达阳性者(P<0.05);经非条件多因素Logistic回归模型进一步分析结果显示CA125阳性、HE4阳性、FIGO分期为Ⅲ~Ⅳ期、盆腔淋巴结阳性、腹主动脉旁淋巴结阳性、有腹水、浸润深度≥1/2、病理学分级(G3)是影响上皮性卵巢癌患者预后的独立危险因素(P<0.05)。结论CA125、HE4术前阳性表达在上皮性卵巢癌患者中死亡率较高,临床可通过联合检测CA125、HE4水平,提高早期上皮性卵巢癌患者的诊断率,更有利于评估患者病情进展和预后。 Objective To analyze the application of serum carbohydrate antigen 125(CA125)combined with human epididymis protein 4(HE4)in assessing the disease and predicting the prognosis of the survival of patients with epithelial ovarian cancer.Methods The clinical data of 54 patients with epithelial ovarian cancer from May 2016 to May 2017 were retrospectively analyzed.The patients were set as the experiment group.Another 60 healthy women undergoing physical examination during the same period were selected as the control group.The serum CA125 and HE4 expression levels between the two groups were compared.The relationship between CA125 and HE4 levels and the clinicopathological characteristics of patients with epithelial ovarian cancer was analyzed.ROC curve was drawn and Keplan-meier survival analysis was used to compare the prognosis.Logistic regression model was used to explore the relevant factors affecting the prognosis.Results The positive expression rates of CA125 and HE4 in the experiment group were significantly higher than those in the control group(P<0.05).The older the age was,the deeper the depth of tumor invasion was,the higher the pathological grade was,the higher the positive expression rates of CA125 and HE4 were(P<0.05).In FIGO staging,the positive expression rate of patients in stage III to IV was significantly higher than that of patients in stageⅠtoⅡ(P<0.05).The positive expression rate of CA125 and HE4 in patients with positive pelvic lymph nodes,positive para-aortic lymph nodes,and ascites was significantly higher than that of patients without lymph node metastasis and ascites(P<0.05).Keplan-meier analysis showed that the survival time of patients with CA125 and HE4 negative expression was significantly longer than that of patients with positive expression(P<0.05).Further analysis of the unconditional multivariate logistic regression model showed that positive CA125,positive HE4,FIGO stageⅢ-Ⅳ,positive pelvic lymph nodes,positive abdominal para-aortic lymph nodes,ascites,depth of invasion≥1/
作者 毛爱荣 李战飞 袁晓雁 韩玉新 陈静 MAO Ai-rong;LI Zhan-fei;YUAN Xiao-yan;HAN Yu-xin;CHEN Jing(Jiaozuo District Hospital,988 Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Jiaozuo 454150,China;Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)
出处 《实用医院临床杂志》 2021年第5期78-82,共5页 Practical Journal of Clinical Medicine
基金 河南省医学科技攻关计划省部共建项目(编号:SB201701043)。
关键词 糖类抗原125 人附睾蛋白4 上皮性卵巢癌 病理特征 CA125 HE4 Epithelial ovarian cancer Pathological features
  • 相关文献

参考文献11

二级参考文献56

  • 1Joshua G Cohen,Matthew White,Ana Cruz,Robin Farias-Eisner.WJBC 5^(th) Anniversary Special Issues(2): Proteomics In 2014, can we do better than CA125 in the early detection of ovarian cancer?[J].World Journal of Biological Chemistry,2014,5(3):286-300. 被引量:18
  • 2SIEGEL R, NA1SHADHAM D, JEMAL A. Cancer statistics, 2013[J]. CA-A Cancer Journal for Clinicians, 2013, 63 (1): 11 -30. 被引量:1
  • 3XU Xia, WANG Yan, WANG Fang, et al. Nadir CA - 125.level as prognosis indicator of high - grade serous ovarian cancer [ J ]. Journal of Ovarian Research, 2013, 6 (1): 31 -33. 被引量:1
  • 4STEFFENSEN K D, WALDSTR? M M, BRANDSLUND I, et al. The prognostic and predictive value of combined HE4 and CA -125 in ovarian cancer patients [ J ]. International Joumal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2012, 22 (9) : 1474 -1482. 被引量:1
  • 5KRYCZEK I, BANERJEE M, CHENG P, et al. Phenotype, distribution, Generation, and functional and clinical relevance of Thl7 cells in the human tumor environments [J]. Blood, 2009, 114 (6) : 1141 -1149. 被引量:1
  • 6WU Xiaoqin, ZENG Zhirong, CHEN Bin, et al. Association between polymorphisms in interleukin - 17A and interleukin - 17F genes and risks of gastric cancer [ J]. International Journal of Cancer. Joumal International du Cancer, 2010, 127 (1): 86 -92. 被引量:1
  • 7MOORE R G, MACLAUGHLAN S, BAST R C. Current state of biomarker development for clinical application in epithelial ovarian cancer [J]. Gynecologic Oncology, 2010, 116 (2) : 240 -245. 被引量:1
  • 8HELLSTR? M I, RAYCRAFY J, HAYDEN - LEDBE'I3'ER M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Research, 2003, 63 ( 13 ) : 3695 - 3700. 被引量:1
  • 9董丽,昌晓红,叶雪,朱丽荣,赵旸,田莉,程洪艳,李小平,张虹,廖秦平,付天云,成夜霞,崔恒.血清人附睾分泌蛋白4和CA125水平检测在卵巢恶性肿瘤中的诊断价值[J].中华妇产科杂志,2008,43(12):931-936. 被引量:98
  • 10王术艺,李洪臣,董立新,王学为,王猛.一种新的肿瘤标志物HE4在妇科盆腔恶性肿瘤诊断中的应用[J].中华微生物学和免疫学杂志,2009,29(1):93-94. 被引量:4

共引文献133

同被引文献84

引证文献7

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部